D
Daniel T. Lioy
Researcher at Oregon Health & Science University
Publications - 12
Citations - 2130
Daniel T. Lioy is an academic researcher from Oregon Health & Science University. The author has contributed to research in topics: Rett syndrome & MECP2. The author has an hindex of 10, co-authored 11 publications receiving 1956 citations. Previous affiliations of Daniel T. Lioy include Howard Hughes Medical Institute & Vollum Institute.
Papers
More filters
Journal ArticleDOI
Homeostatic regulation of MeCP2 expression by a CREB-induced microRNA.
TL;DR: It is found that MeCP2 translation is regulated by microRNA 132 (miR132) and this feedback loop may provide a mechanism for homeostatic control of Me CP2 expression.
Journal ArticleDOI
A role for glia in the progression of Rett's syndrome.
Daniel T. Lioy,Saurabh K. Garg,Saurabh K. Garg,Caitlin E. Monaghan,Caitlin E. Monaghan,Jacob Raber,Jacob Raber,Kevin D. Foust,Brian K. Kaspar,Petra G. Hirrlinger,Frank Kirchhoff,John M. Bissonnette,Nurit Ballas,Gail Mandel,Gail Mandel +14 more
TL;DR: It is shown that glia, like neurons, are integral components of the neuropathology of RTT, and supports the targeting of glia as a strategy for improving the associated symptoms.
Journal ArticleDOI
Non-cell autonomous influence of MeCP2-deficient glia on neuronal dendritic morphology
TL;DR: These studies suggest that astrocytes in the RTT brain carrying MeCP2 mutations have a non–cell autonomous effect on neuronal properties, probably as a result of aberrant secretion of soluble factor(s).
Journal ArticleDOI
microRNA-132 regulates dendritic growth and arborization of newborn neurons in the adult hippocampus
Stephen T. Magill,Xiaolu A. Cambronne,Bryan W. Luikart,Daniel T. Lioy,Barbara H. Leighton,Gary L. Westbrook,Gail Mandel,Richard H. Goodman +7 more
TL;DR: It is concluded that miR-132 is required for normal dendrite maturation in newborn neurons in the adult hippocampus and suggested that this microRNA also may participate in other examples of CREB-mediated signaling.
Journal ArticleDOI
Systemic delivery of MeCP2 rescues behavioral and cellular deficits in female mouse models of Rett syndrome.
Saurabh K. Garg,Daniel T. Lioy,Daniel T. Lioy,Hélène Cheval,James C. McGann,James C. McGann,John M. Bissonnette,Matthew J. Murtha,Kevin D. Foust,Brian K. Kaspar,Adrian Bird,Gail Mandel,Gail Mandel +12 more
TL;DR: It is shown that self-complementary AAV9, bearing MeCP2 cDNA under control of a fragment of its own promoter (scAAV9/MeCP2), is capable of significantly stabilizing or reversing symptoms when administered systemically into female RTT mice, the first potential gene therapy for females afflicted with RTT.